Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Cancer Treat Rev. 2009 Mar 4;35(5):475–484. doi: 10.1016/j.ctrv.2009.02.003

Table 3.

Quality of Study Methodology and Reporting

1980–1998 1999–2005 All
n % n % n %
Sample description
 Reported number approached to participate 88 36.5 112 45.3 200 41.0
 Reported number initially participating* 210 87.1 232 93.9 442 90.2
 Compared characteristics of participants to eligible non- participants 17 7.1 19 7.7 36 7.4
 Reported number dropping out of treatment 101 41.9 116 47.0 217 44.5
Research Design
 One group post test only 10 4.1 7 2.8 17 3.5
 One group pre and post test 36 14.9 58 23.5 94 19.3
 Nonequivalent control group without matching or statistical control 26 10.8 13 5.3 39 8.0
 Nonequivalent control group with matching or statistical control 9 3.7 4 1.6 13 2.7
 Randomized experiment 150 62.2 157 63.6 307 62.9
 Other design/design not indicated 10 4.1 8 3.2 18 3.7
 Quality of randomization, for randomized experiments (n = 307)*b
  Randomization implied but not stated 2 1.3 1 0.6 3 1.0
  Method only stated to be randomized 88 58.7 81 51.6 169 55.0
  Randomization procedure described but no measures to prevent subterfuge included 42 28.0 37 23.6 79 25.7
  Randomization procedure described and measures to prevent subterfuge included 18 12.0 38 24.2 56 18.2
Intervention provision and specification
 Manuals used to guide treatment (where applicable, n = 607 intervention conditions) 87 27.3 93 32.5 182 30.0
 Intervention implementation assessed
  Intervention monitoreda*** 116 48.1 159 64.4 275 56.4
  Assessed immediate effects of interventiona 26 10.8 28 11.3 54 11.1
 Additional intervention monitored 37 15.3 41 16.6 78 16.0
 Contamination monitored (where applicable, n =368) 20 8.2 25 10.1 45 12.2
 Process analyses conducted
  Linked intervention elements or duration to outcomea 38 15.7 37 15.0 75 15.4
  Examined mediating factorsa 29 12.0 25 10.1 54 11.1
Data Analyses
 Groups compared for equivalence at baseline (where applicable, n = 375)** 155 79.0 163 90.5 317 84.5
 Interaction between treatment condition and dropout status (re: study treatment or follow-up on pretreatment variables examined, where applicable n = 365) 4 1.1 9 2.4 13 3.6
 Intent-to-treat analyses conducted** 21 8.7 44 17.8 65 13.3
a

Categories not mutually exclusive.

b

df = 3.

*

p < .05.

**

p < .01.

***

p < .001.